A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Clinical trial NCT05643742 · RECRUITING

Trial details

NCT number: NCT05643742
Sponsor: CRISPR Therapeutics AG
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

B-cell Lymphoma Non-Hodgkin Lymphoma B-cell Malignancy Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Large B-cell Lymphoma

Start date: 2023-03-10
Primary completion: 2030-01-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.